Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0085593 (chills)
 4,268 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Human fibroblast interferon(HFIF) was used in 26 patients with various malignant diseases, most of whom had previous chemotherapy. The dosages used were 3 X 10(6) IU or 6 X 10(6) IU of HFIF i. v. daily. Out of 24 evaluable patients, there were 2 partial remissions (CLL 1 and multiple myeloma 1), and 7 stable diseases (multiple myeloma 2, stomach cancer 2, non-Hodgkin's lymphoma 1, CLL 1 and malignant melanoma 1). The majority of the patients experienced fever exceeding 38 degrees C and chills, which became uncommon within several days of treatment. Other side effects included myelosuppression, general malaise, anorexia, hepatic dysfunction and renal dysfunction, which were mild and tolerable.
 ...
PMID:[Clinical effects of human fibroblast interferon on malignant tumors]. 718 62

Eight patients, 7 with hidradenitis suppurativa and 1 with chronic recurrent staphylococcal abscess, all of whom failed to respond to antibiotic therapy, conservative therapeutic measures, and surgery, were experimentally placed on Staphage Lysate. Treatment after appropriate skin testing consisted of subcutaneous infections of 0.1 ml and intranasal installation of 0.3 ml of Staphage Lysate. Treatments were weekly for twelve weeks, biweekly for six months, and then monthly. Complications, which occurred early, were minimal and involved rash, vertigo, malaise, chills, nausea, fever, and headache. Six of the 8 patients reported noticeable improvement in odor, consistency, and amount of drainage and considerable decreases in pain. Seven of the 8 patients reported improvement in the ability of lesions to drain spontaneously, and a decrease in the frequency of inflammatory nodules. All 8 patients reported that the inflammatory periods were definitely shorter. Early data suggests that Staphage Lysate is a useful adjuvant in the treatment of hidradenitis suppurativa.
 ...
PMID:A preliminary report on the use of Staphage Lysate for treatment of hidradenitis suppurativa. 724 54

The prognostic importance of various factors was analyzed for 347 patients registered by the Mycosis Fungoides Cooperative Group (MFCG). Extent of skin involvement at the time of registration and number of sites of clinically enlarged lymph nodes were clearly the most important prognostic variables, and were combined into a single variable, TN stage, for adjusted analyses of other factors. Sex, history of tonsillectomy, immunoglobulin E, and telangiectasia did not significantly affect survival. The effects of race and allergic history were questionable and need further study. Age, pruritus, burning, alopecia, ulcers, and erosion were important when studied alone, but their effects were no longer statistically significant after adjustment for TN stage. Chills and malaise, the latter a symptom of debility, retained prognostic significance after such adjustment. This analysis demonstrates the importance of considering the joint effects of multiple prognostic factors rather than analyzing them one at a time.
 ...
PMID:Prognostic variables in mycosis fungoides. 726 Aug 60

Fifteen adult patients with advanced solid tumors received bruceantin at doses of 1.6-6.0 mg/m2 iv for 30 minutes/week X 4, followed by a 2-week rest. The dose-limiting toxic effect was nausea and vomiting, which was more severe in patients with hepatic metastases or liver function abnormalities. Other sporadic toxic effects included fever, chills, malaise, alopecia, hypotension, thrombocytosis, and leukocytosis. Hematologic toxicity was insignificant. The recommended starting dose for phase II studies is 5 mg/m2/week X 4, every 6 weeks, with a reduction to 3 mg/m2 for patients with hepatic metastases.
 ...
PMID:Phase I study on bruceantin administered on a weekly schedule. 727 23

Airborne Gram-negative bacteria contamination has been demonstrated in several environments like cotton or flax factories, rooms with humidifiers and sewage treatment plants. Inhalation of LPS by animals provokes a bronchial invasion by neutrophils, a platelet aggregation in pulmonary capillaries, a local immune response and fever. Inhalation by human is related with clinical symptoms like fever, chills, malaise, muscle and joint aches and chest thightness. It appears from data in the literature that LPS airborne contamination is sufficient to provoke such symptoms. It seems important to study more precisely the contamination of suspected air in presence of these symptoms.
 ...
PMID:Effects of bacterial endotoxin inhalation. 728 Mar 43

Stress-induced diabetic ketoacidosis is characterized by an elevation in stress hormone concentration. Whether metabolic decompensation induces or results from the secretion of stress hormones has not been examined. Our study examined the temporal relationship between the onset of stress (pyrogen-induced shaking chills and fever); the elevation in stress hormone concentation; and the rise in plasma glucose, ketone bodies, and nonesterified fatty acid concentration. Insulin deficiency, which may itself induce stress hormone secretion, was prevented by the continuous infusion of insulin (0.01 U/kg.h). Pyrogen administration induced malaise and fever in all diabetic volunteers and the rapid endogenous secretion of all stress hormones. The rise in plasma GH, catecholamines, and cortisol preceded the rise in plasma nonesterified fatty acid and ketone body concentrations by at least 30 min. The rise in plasma glucagon concentration preceded the rise in plasma glucose concentration by at lease 1 h. Thus, these studies support a primary role for stress hormones in initiating metabolic decompensation in stressed diabetic man.
 ...
PMID:The temporal relationship between endogenously secreted stress hormones and metabolic decompensation in diabetic man. 735 Jan 76

An explosive outbreak of influenza caused by an A/USSR/77-like (H1N1) virus occurred aboard a US Navy ship in December 1977 and January 1978. Two hundred volunteers aboard the ship were studied. Virus was isolated from 36 of 57 patients from whom isolation was attempted. Among virologically confirmed patients, headache (97%), chills (92%), malaise (86%), and cough (75%) were the most frequent symptoms. There were two virologically confirmed cases with complications: one with collapsed lung and the other with pneumonitis. The study subjects were 25 years of age or less, but there was little influenza-like disease in members of the crew greater than 25 years of age. Prior vaccination with bivalent vaccine, containing A/NJ/76 (Hsw1N1) virus, did not offer significant protection against disease caused by A/USSR/77-like virus. Serologic tests, either or both complement fixation and hemagglutination inhibition, were positive in only 14 of 22 virologically confirmed cases, indicating a poor serologic response to primary infection with this strain of virus. These findings prevented calculation of meaningful disease to infection ratios. However, inapparent infection occurred in 3 of 19 (16%) individuals who denied having illness during the outbreak yet had serologic evidence of recent influenza infection.
 ...
PMID:An influenza outbreak due to A/USSR/77-like (H1N1) virus aboard a US Navy ship. 742 98

Three subjects, all smokers, handling stainless steel tubes suffered repeated attacks of general malaise, chills, and fever lasting for several hours, mainly after gas soldering. Provocations by rubbing smoking tobacco against a tube produced similar attacks, and leucocytosis, after a few hours. The presence of fluorine on the tubes and in the febrifacient tobacco was shown. A fluorocarbon polymer lubricant was suspected of causing the attacks. Heating (1000 degrees C) of the tubes eliminated the effect.
 ...
PMID:Fever induced by fluorine-containing lubricant on stainless steel tubes. 742 82

OBJECTIVE--To study the effect of anti-CD4 treatment in patients suffering from refractory systemic onset juvenile chronic arthritis (JCA). METHODS--Two children were treated with the mouse CD4 antibody MAX.16H5. The effects on numbers of circulating CD4 T cells, clinical symptoms and C reactive protein (CRP) level were studied and the appearance of human antimouse immunoglobulin antibodies investigated. RESULTS--In patient one, disappearance of fever and malaise and a reduction of arthritic activity were observed together with a reduction in CRP. When disease activity returned eight weeks later, a second successful course of treatment was administered. It was possible to reduce the corticosteroid dosage permanently. In the other child, a first treatment cycle did not alter disease activity. A marked reduction in clinical and laboratory disease activity markers was observed after the second course. Only transient and mild side effects were observed. One patient exhibited a short lasting febrile reaction with chills, the other an urticarial rash. In both patients, human antibodies to mouse immunoglobulin became detectable. The decrease in the number of CD4 T cells in the peripheral blood was only short lasting and numbers returned to normal values within one to eight weeks, even after the second course of antibody treatment and under concomitant immunosuppressive treatment. No sustained clinical remissions could be achieved. CONCLUSIONS--These preliminary observations support the evidence of positive effects of CD4 antibody treatment in refractory systemic onset JCA. Long term efficacy, however, remains to be established.
 ...
PMID:Treatment of refractory juvenile chronic arthritis by monoclonal CD4 antibodies: a pilot study in two children. 749 26

We conducted a phase I/II clinical trial evaluating the sequential outpatient combination of S.C. recombinant human interleukin-2 (rIL-2; given at 10 MIU/m2 b.i.d. on days 3-5 weeks 1 and 4 and at 5 MIU/m2 on days 1, 3, and 5 of weeks 2 and 3), s.c. recombinant human alpha-interferon (rIFN-alpha; given at 6 MIU/m2 on day 1 of weeks 1 and 4 and on days 1, 3, and 5 of weeks 2 and 3 and at 9 MIU/m2 on days 1, 3, and 5 of weeks 5-8), i.v. bolus 5-fluorouracil (5-FU; given at 1,000 mg/m2 once weekly during weeks 5-8), and i.v. bolus vinblastine (given at 6 mg/m2 once weekly during weeks 5 and 8) in conjunction with p.o. 13-cis-retinoic acid (13-C-RA; given at 35 mg/m2 daily during weeks 1-8). Therapy was always given in the outpatient setting. Grade 3 constitutional symptoms (malaise, chills, fevers, anorexia) were observed in 4%-8% of treatment cycles and required a 50% reduction in the doses of rIL-2 and rIFN-alpha. None of the patients experienced major 5-FU-related toxicities such as severe diarrhea and/or stomatitis; up to 20% of patients developed vinblastine-associated peripheral polyneuropathy, which was reversible after the cessation of therapy. 13-cis-Retinoic acid produced no significant side effect; no toxic death occurred. Among 24 patients with progressive metastatic disease, there were 4 complete remissions (lung, lymph nodes) and 6 partial remissions (lung, pleura, liver, lymph nodes, and peritoneal carcinosis), for an overall objective response rate of 42% (95% confidence interval, 22%-63%).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. 755 Mar 91


<< Previous 1 2 3 4 5 6 7 8 9 10